Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric.
Read More
DNB//Back Bay is pleased to sponsor the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
Read More
With biopharma pouring more money than ever into weight loss medicines, physicians would like to see improved GLP-1 drugs. But the goals of the two parties are not in full alignment, according to a new study from financing partner DNB Markets and strategic advisory firm Back Bay Life Science Advisors.
Read More
This two-day equity conference is by invitation to institutional healthcare specialist and generalist investors, industry experts, corporate development, and healthcare executives. The NAHC includes sector-specific panel discussions with insights from DNB healthcare equity analysts, industry leaders, and investors.
Read MoreThe commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.
Read More